Table 2 Microbiological outcomes and side effects for patients, by province

Total

n = 494

n = 168

n = 662

Treatment duration [median (IQR)]

 Start to completion (months)

19.0 (9.8–20.0)

20.0 (9.7–21.3)

19.0 (9.7–20.0)

 Inpatient regimen (days)

25 (16–34)

33 (19–42)

28 (16–37)

Smear conversion after 2 months

n = 454

n = 132

n = 586

 Yes

418 (92.1%)

85 (64.4%)

503 (85.8%)

 No

36 (7.9%)

47 (35.6%)

83 (14.2%)

 Not reported

40

36

76

Smear conversion after 4 months

n = 421

n = 116

n = 537

 Yes

409 (97.1%)

110 (94.8%)

519 (96.6%)

 No

12 (2.9%)

6 (5.2%)

18 (3.4%)

 Not reported

73

52

125

Culture conversion after 2 months

n = 448

n = 105

n = 553

 Yes

405 (90.4%)

10 (9.5%)

415 (75.0%)

 No

43 (9.6%)

95 (90.5%)

138 (25.0%)

 Not reported

46

63

109

Culture conversion after 4 months

n = 420

n = 108

n = 528

 Yes

402 (95.7%)

86 (79.6%)

488 (92.4%)

 No

18 (4.3%)

22 (20.4%)

40 (7.6%)

 Not reported

74

60

134

Side effects during treatment

 At least one inpatient side effect reported

n = 308

n = 144

n = 452

  Yes

23 (7.5%)

16 (11.1%)

39 (8.6%)

  No

285 (92.5%)

128 (88.9%)

413 (91.4%)

  Not reported

186

24

210

 At least one outpatient side effect reported

n = 447

n = 125

n = 572

  Yes

75 (16.8%)

32 (25.6%)

107 (18.7%)

  No

372 (83.2%)

93 (74.4%)

465 (81.3%)

  Not reported

47

43

90

 Outpatient side effects reported^a

n = 195

n = 52

n = 247

  Blood disorder

6 (3.1%)

0 (0%)

6 (2.4%)

  Bowel pain

3 (1.5%)

2 (3.8%)

5 (2.0%)

  Hearing loss

9 (4.6%)

3 (5.8%)

12 (4.9%)

  Hepatotoxicity

35 (17.9%)

0 (0%)

35 (14.2%)

  High blood sugar

10 (5.1%)

0 (0%)

10 (4.0%)

  High uric acid

42 (21.5%)

0 (0%)

42 (17.0%)

  Hypokalemia

15 (7.7%)

0 (0%)

15 (6.1%)

  Joint pain

19 (9.7%)

16 (30.8%)

35 (14.2%)

  Loss of appetite

11 (5.6%)

0 (0%)

11 (4.5%)

  Nephrotoxicity

17 (8.7%)

0 (0%)

17 (6.9%)

  Neurotoxicity

7 (3.6%)

1 (1.9%)

8 (3.2%)

  Nausea

0 (0%)

23 (44.2%)

23 (9.3%)

  Vision loss

7 (3.6%)

2 (3.8%)

9 (3.6%)

  Vertigo

14 (7.2%)

5 (9.6%)

19 (7.7%)

  Not reported

299

116

415